Department of Organic and Pharmaceutical Technology, Faculty of Chemistry, Wroclaw University of Technology, Wybrzeże Wyspiańskiego 27, 50-370 Wrocław, Poland.
Department of Medical Biochemistry, Medical University, Chałubińskiego 10, 50-368 Wrocław, Poland.
Photodiagnosis Photodyn Ther. 2014 Dec;11(4):570-85. doi: 10.1016/j.pdpdt.2014.10.005. Epub 2014 Oct 28.
Searching for photodynamic therapy (PDT) - effective nanocarriers which enable a photosensitizer to be selectively delivered to tumor cells with enhanced bioavailability and diminished dark cytotoxicity is of current interest. The main objective of this study is to evaluate newly designed mixed polymeric micelles based on Pluronics P123 and F127 for the improved delivery of Photofrin II(®) (Ph II(®)) to circumvent unfavorable effects overcoming multidrug resistance (MDR) in tumor cells - in breast MCF-7/WT (caspase-3 deficient) and ovarian SKOV-3 (resistant to chemotherapy).
Ph II(®)-loaded micelles were obtained and analyzed for size and morphology, solubilization efficiency, physical stability and in vitro drug release. Intracellular uptake, reactive oxygen species (ROS) generation, mitochondrial oxidoreductive potential and proapoptotic activity (TUNEL assay) studies were evaluated in the examined cancer cells. The preliminary biocompatibility characteristics of all nanocarriers was determined by assessment of their hemolytic activity in human erythrocytes and dark toxicity in cancer cells.
Dynamic light scattering (DLS) and atomic force microscopy (AFM) confirmed that almost monodisperse, sphere-shaped and nanosized (DH<20 nm) carriers were developed. Biological studies after photodynamic reaction (PDR) with encapsulated Ph II(®) revealed increased ROS level, malondialdehyde (MDA) concentration and protein damage in SKOV-3 and MCF-7/WT cells in comparison to treatment with free Ph II(®). Numerous apoptotic cells were detected after nano-therapy in both cell lines, with observed significant morphological disorders in ovarian cancer cells. In the case of encapsulated Ph II(®) only negligible disruption of human erythrocytes and cancer cells was observed.
The obtained biocompatible long-lasting nanocarriers significantly enhance the Photofrin II(®) photodynamic effect and apoptosis in both SKOV-3 and MCF-7/WT cell lines.
寻找光动力疗法(PDT)-有效的纳米载体,使光敏剂能够选择性地递送到肿瘤细胞,提高生物利用度并降低暗细胞毒性,这是当前的研究热点。本研究的主要目的是评估基于 Pluronics P123 和 F127 的新型混合聚合物胶束,以改善 Photofrin II(®)(Ph II(®))的递药,以规避多药耐药(MDR)在肿瘤细胞中的不利影响-在乳腺癌 MCF-7/WT(半胱天冬酶-3 缺陷)和卵巢 SKOV-3(对化疗耐药)中。
负载 Ph II(®)的胶束被获得并分析其大小和形态、增溶效率、物理稳定性和体外药物释放。在研究的癌细胞中评估细胞内摄取、活性氧(ROS)生成、线粒体氧化还原电势和促凋亡活性(TUNEL 测定)。通过评估纳米载体对人红细胞的溶血活性和对癌细胞的暗毒性,初步确定了所有纳米载体的生物相容性特征。
动态光散射(DLS)和原子力显微镜(AFM)证实,几乎单分散、球形和纳米级(DH<20nm)的载体被开发出来。与游离 Ph II(®)相比,用包裹的 Ph II(®)进行光动力反应(PDR)后的生物学研究显示,ROS 水平、丙二醛(MDA)浓度和蛋白质损伤在 SKOV-3 和 MCF-7/WT 细胞中增加。在两种细胞系中,纳米治疗后均检测到大量凋亡细胞,观察到卵巢癌细胞的形态异常明显。在包裹的 Ph II(®)的情况下,仅观察到对人红细胞和癌细胞的可忽略的破坏。
获得的生物相容性长持续时间的纳米载体显著增强了 Photofrin II(®)在 SKOV-3 和 MCF-7/WT 细胞系中的光动力效应和细胞凋亡。